Nasal Polyps pipeline Research Monitor, 2020- Drugs, Companies, Clinical Trials, R&D pipeline updates, status and outlook

July 2020 | 54 pages | ID: N60F768FD21CEN
VPAResearch

Abstracts

2020 Nasal Polyps PIPELINE HIGHLIGHTS
Nasal Polyps is one of the widely researched conditions during 2020 with 9 companies actively focusing on realizing pipeline’s potential. Development of Nasal Polyps medicines is identified as integral to the strategy of the majority of companies operating in the industry.
Global Nasal Polyps market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Nasal Polyps .

Good progress is anticipated during 2020 and 2021 with Nasal Polyps pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Nasal Polyps pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.
Nasal Polyps DRUG DEVELOPMENT PIPELINE OVERVIEW
The “Nasal Polyps pipeline Research Monitor, 2020” report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.
This Nasal Polyps pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.

The competitive intelligence report on Nasal Polyps presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Nasal Polyps pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report.
Nasal Polyps DRUG PROFILES
Nasal Polyps development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided-

• Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others.
• Phase of development
• Mechanism of Action
• Route of Administration
• Companies involved including originator, licensing companies, developer, investors, and others
• New molecular entity details
• Orphan drug designation and other special status provided by regulators

Nasal Polyps COMPANY PROFILES

Both small size and large size pharmaceutical companies are investing their resources in Nasal Polyps drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Nasal Polyps . Partnerships and acquisitions are also increasingly observed in the pipeline.

This research report presents an analysis of 9 Nasal Polyps companies including company overview, key snapshot, contact information, and their strategies on accelerating Nasal Polyps pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.

Companies analyzed in the report include- AnaptysBio Inc, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Idorsia Pharmaceutical Ltd, Kyowa Hakko Kirin Co Ltd, Novartis AG, OptiNose US Inc, Pfizer Inc, Suzhou Connect Biopharmaceuticals Ltd

REASONS TO BUY

• The current market conditions are forcing companies and investors worldwide to prioritize their investments and accelerate pipeline candidates only through careful quantitative assessment.
• This research work assists decision makers in pharmaceutical companies towards successful pipeline development through critically evaluated pipeline data
• Buyers can identify most promising drug candidates for treatment of Nasal Polyps
• It allows users to strengthen their pipeline through acquisitions, licensing and collaborations
• Users can estimate possible delays in the delivery of pipeline or launch of new products
• Stay ahead of competition through understanding their pipeline progression, strategies and outlook
• The report details all the pipeline candidates under investigation in various stages of development from Phase I through to Phase III to enable business development managers to understand the impact of new launches.
• Optimize your licensing and technology transfer strategies through identification of prospect partners

Contents

1. INTRODUCTION TO NASAL POLYPS

1.1 Nasal Polyps - Disease overview
1.2 Nasal Polyps - Market Size
1.3 Nasal Polyps - Companies Involved

2. NASAL POLYPS PIPELINE SNAPSHOT- 2020

2.1 Nasal Polyps Pipeline by Phase
2.2 Nasal Polyps Pipeline by Mechanism of Action
2.3 Nasal Polyps Pipeline by Route of Administration
2.4 Nasal Polyps Pipeline- New Molecular Entities
2.5 Nasal Polyps Pipeline- Orphan Drug Designation/ Special Designation

3. NASAL POLYPS DRUG PROFILES

3.1 Current Status
3.2 Nasal Polyps Drug Snapshot
3.3 Nasal Polyps Therapeutic Candidates- Originator/Licensor
3.4 Route of Administration
3.5 Mechanism of Action
3.6 NME
4.1 AnaptysBio Inc Nasal Polyps Pipeline Insights and Clinical Trials
4.2 F. Hoffmann-La Roche Ltd Nasal Polyps Pipeline Insights and Clinical Trials
4.3 GlaxoSmithKline Plc Nasal Polyps Pipeline Insights and Clinical Trials
4.4 Idorsia Pharmaceutical Ltd Nasal Polyps Pipeline Insights and Clinical Trials
4.5 Kyowa Hakko Kirin Co Ltd Nasal Polyps Pipeline Insights and Clinical Trials
4.6 Novartis AG Nasal Polyps Pipeline Insights and Clinical Trials
4.7 OptiNose US Inc Nasal Polyps Pipeline Insights and Clinical Trials
4.8 Pfizer Inc Nasal Polyps Pipeline Insights and Clinical Trials
4.9 Suzhou Connect Biopharmaceuticals Ltd Nasal Polyps Pipeline Insights and Clinical Trials

5. NASAL POLYPS MARKET NEWS AND UPDATES

6. APPENDIX

6.1 Sources and Methodology
6.2 Contact Information